Abstract: The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The present invention also relates to a method of identifying a compound suitable for the treatment of multiple sclerosis in a patient.

Abstract: The present invention provides a process for preparing an unsaturated alcohol of the formula (I), wherein one of R1 and R2 is preferably C2-C10-alkyl or C2-C10-alkenyl containing one double bond and the other one is preferably hydrogen or methyl; R3 is preferably hydrogen; which comprises subjecting an educt composition including at least 75% by weight of an unsaturated aldehyde of the formula (II) wherein R1, R2 and R3 preferably have the above defined meanings, to a hydrogenation in the presence of a catalyst and a tertiary amine; wherein the tertiary amine is used in an amount ranging from 0.001 to 0.7% by weight, based on the total amount of the liquid reaction mixture.

Abstract: The present invention relates to a process for purifying ethoxyquin by distillation, to high-purity ethoxyquin obtainable by means of distillative purification and to the use thereof, particularly as additive in foodstuffs and feedstuffs.

Abstract: The present invention relates to a method for diagnosing breast cancer in a patient or for determining whether a patient will respond to a therapeutic treatment of breast cancer. Further, the present invention relates to the use of at least one polynucleotide for detecting at least one miRNA for diagnosing breast cancer in a blood sample from a patient or for determining whether a patient will respond to a therapeutic treatment of breast cancer in a blood sample from the patient. Furthermore, the present invention relates to the use of at least one miRNA isolated from a blood sample from a patient for diagnosing breast cancer or for determining whether the patient will respond to a therapeutic treatment of breast cancer. In addition, the present invention relates to a kit for diagnosing breast cancer in a patient or for determining whether a patient will respond to a therapeutic treatment of breast cancer.

Abstract: A strapping apparatus for strapping articles with a strapping band having a tensioning device for imparting a band tension to a loop of the strapping band, the tensioning device including a driveable tensioning element provided for engaging the strapping band to impart a band tension. The strapping apparatus including a connecting device for generating a permanent connection, in particular a welded connection, at two regions, situated one above the other, of the loop of the strapping band. The strapping apparatus is configured to achieve the release of the tensioning element from the strapping band reliably to avoid or reduce adverse characteristics attributed to the release of the tensioning device from the band.

Abstract: A system operating in a plurality of modes to provide an integrated analysis of molecular data, imaging data, and clinical data associated with a patient includes a multi-scale model, a molecular model, and a linking component. The multi-scale model is configured to generate one or more estimated multi-scale parameters based on the clinical data and the imaging data when the system operates in a first mode, and generate a model of organ functionality based on one or more inferred multi-scale parameters when the system operates in a second mode. The molecular model is configured to generate one or more first molecular findings based on a molecular network analysis of the molecular data, wherein the molecular model is constrained by the estimated parameters when the system operates in the first mode.

Abstract: Process for the preparation of alpha, beta unsaturated aldehydes by oxidation of alcohols where the oxidant is oxygen in the presence of a catalyst comprising platinum on a support in the presence of a liquid phase which contains at least 25 weight-% water based on the total weight of the liquid phase.

Abstract: The present invention relates to a process for the preparation of an optically active carbonyl compound by asymmetric hydrogenation of a prochiral ?,?-unsaturated carbonyl compound with hydrogen in the presence of at least one optically active transition metal catalyst that is soluble in the reaction mixture and which has rhodium as catalytically active transition metal and a chiral, bidentate bisphosphine ligand, wherein the reaction mixture during the hydrogenation of the prochiral ?,?-unsaturated carbonyl compound additionally comprises at least one compound of the general formula (I): in which R1, R2: are identical or different and are C6- to C10-aryl which is unsubstituted or carries one or more, e.g. 1, 2, 3, 4 or 5, substituents which are selected from C1- to C6-alkyl, C3- to C6-cycloalkyl, C6- to C10-aryl, C1- to C6-alkoxy and amino; Z is a group CHR3R4 or aryl which is unsubstituted or carries one or more, e.g.

Abstract: Using the full repertoire of genetic information from bacterial genomes and plasmids for improved genetic resistance tests The invention relates to a method of determining an antimicrobial drug resistance profile for a microorganism, wherein nucleic acid sequences of the microorganism are analyzed for at least two genetic variations of the nucleic acid sequences comprising at least one genetic variation in a chromosome and at least one genetic variation in at least one plasmid, as well as a, e.g. diagnostic, method of determining an infection of a patient with a microorganism potentially resistant to antimicrobial drug treatment and a method of selecting a treatment of a patient suffering from an infection with a potentially resistant microorganism, wherein the data of the antimicrobial drug resistance profile are applied.

Abstract: The invention relates to a method of determining an infection of a patient with Serratia species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Serratia infection, and a method of determining an antibiotic resistance profile for bacterial microorganisms of Serratia species, as well as computer program products used in these methods. In an exemplary method, a sample (1), is used for molecular testing (2), and then a molecular fingerprint (3) is taken. The result is then compared to a reference library (4), and the result (5) is reported.

Abstract: The invention relates to a method of determining an infection of a patient with Salmonella species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Salmonella infection, and a method of determining an antibiotic resistance profile for bacterial microorganisms of Salmonella species, as well as computer program products used in these methods. In an exemplary method, a sample 1 is used for molecular testing 2, and then a molecular fingerprint 3 is taken. The result is then compared to a reference library 4, and the result 5 is reported.

Abstract: A process for preparing 2,6-dimethyl-5-heptenal, comprising oxidizing citral of which more than 50% are present as geranial with hydrogen peroxide in the presence of a catalyst comprising a Baeyer-Villiger oxidation catalyst, preferably a tin-containing molecular sieve.

Abstract: The invention relates to a method of determining an infection of a patient with Proteus species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Proteus infection, and a method of determining an antibiotic resistance profile for bacterial microorganisms of Proteus species, as well as computer program products used in these methods. In an exemplary method, a sample 1, is used for molecular testing 2, and then a molecular fingerprint 3 is taken. The result is then compared to a reference library 4, and the result 5 is reported.

Abstract: A holder for detachably fastening a flat, approximately rectangular device such as a tablet computer or a smartphone to a part, in particular to a motor vehicle part, said holder comprising a holding mechanism for detachably mounting the device, and a fastening element that is connected to the holding mechanism to connect the holder to the part; a rotary bearing that can rotate about an axis of rotation is connected to the holding mechanism, and a pivot bearing is connected to the rotary bearing and to the fastening element, the rotary bearing includes a first portion that is connected to the holding mechanism as well as a second portion that is connected to the fastening element.

Abstract: The present invention relates to a method of determining an infection of a patient with at least one microorganism, particularly a bacterial microorganism, potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an infection with at least one microorganism, particularly bacterial microorganism, and a method of determining an antimicrobial drug, e.g. antibiotic, resistance profile for at least one microorganism, particularly bacterial microorganism, as well as computer program products used in these methods.

Abstract: The disclosure relates to a method for the diagnosis of Alzheimer's disease (AD) in a patient, wherein the expression profile of miRNAs is determined in a blood sample and a comparison of the expression levels of defined miRNAs with a reference sample is carried out. The disclosure also relates to the use of the defined miRNAs as markers for the diagnosis of Alzheimer's disease and to a kit for the diagnosis of Alzheimer's disease.

Abstract: The invention relates to methods for diagnosing multiple sclerosis with miRNA markers. Diagnosis of multiple sclerosis (MS) can be challenging in patients with atypical presentations and during a first neurological deficit possibly related to inflammatory demyelination. Towards the identification of biomarkers for diagnosis of MS, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified, which have previously not been related to MS according to the microRNA disease database. These miRNAs could potentially serve as future diagnostic biomarkers for MS and help in diagnosis, monitoring disease activity, and evaluation of treatment responses in patients with MS.

Abstract: An incipient wetness impregnation method for preparing a tin-containing zeolitic material having framework type BEA, a novel tin-containing zeolitic material having framework type BEA and its use.